Sökning: WFRF:(Andersson Nadine G) >
Dilemmas on emicizu...
-
Ranta, SusannaKarolinska Institutet,Karolinska University Hospital
(författare)
Dilemmas on emicizumab in children with haemophilia A : A survey of strategies from PedNet centres
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:e9cc324a-ae57-49a3-b6f9-adb6cf1f79db
-
https://lup.lub.lu.se/record/e9cc324a-ae57-49a3-b6f9-adb6cf1f79dbURI
-
https://doi.org/10.1111/hae.14847DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:153715182URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Introduction: Haemophilia A care has changed with the introduction of emicizumab. Experience on the youngest children is still scarce and clinical practice varies between haemophilia treatment centres. Aim: We aimed to assess the current clinical practice on emicizumab prophylaxis within PedNet, a collaborative research platform for paediatricians treating children with haemophilia. Methods: An electronic survey was sent to all PedNet members (n = 32) between October 2022 and February 2023. The survey included questions on the availability of emicizumab, on the practice of initiating prophylaxis in previously untreated or minimally treated patients (PUPs or MTPs) and emicizumab use in patients with or without inhibitors. Results: All but four centres (28/32; 88%) responded. Emicizumab was available in clinical practice in 25/28 centres (89%), and in 3/28 for selected patients only (e.g. with inhibitors). Emicizumab was the preferred choice for prophylaxis in PUPs or MTPs in 20/25 centres; most (85%) started emicizumab prophylaxis before 1 year of age (30% before 6 months of age) and without concomitant FVIII (16/20; 80%). After the loading dose, 13/28 centres administered the recommended dosing, while the others adjusted the interval of injections to give whole vials. In inhibitor patients, the use of emicizumab during ITI was common, with low-dose ITI being the preferred protocol. Conclusion: Most centres choose to initiate prophylaxis with emicizumab before 12 months of age and without concomitant FVIII. In inhibitor patients, ITI is mostly given in addition to emicizumab, but there was no common practice on how to proceed after successful ITI.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Motwani, JayashreeBirmingham Children's Hospital
(författare)
-
Blatny, JanUniversity Hospital Brno
(författare)
-
Bührlen, MartinaKlinikum Bremen-Mitte
(författare)
-
Carcao, ManuelHospital for Sick Children, Toronto
(författare)
-
Chambost, HervéLa Timone University Hospital
(författare)
-
Escuriola, CarmenHaemophilia Centre Rhine Main
(författare)
-
Fischer, KathelijnUniversity Medical Center Utrecht
(författare)
-
Kartal-Kaess, MutluBern University Hospital
(författare)
-
de Kovel, MarloesPedNet Haemophilia Research Foundation
(författare)
-
Kenet, GiliTel-Aviv University
(författare)
-
Male, ChristophMedical University of Vienna
(författare)
-
Nolan, BeatriceOur Lady's Hospital for Sick Children
(författare)
-
d'Oiron, RoselineUniversity of Paris-Saclay
(författare)
-
Olivieri, MartinUniversity Hospital Munich
(författare)
-
Zapotocka, EsterUniversity Hospital Motol
(författare)
-
Andersson, Nadine G.Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Enheten för pediatrisk hematologi,Forskargrupper vid Lunds universitet,Pediatrisk hematologi,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Paediatric Hematologic Research Group,Lund University Research Groups,Paediatric Haematology Research Unit(Swepub:lu)med-nge
(författare)
-
Königs, ChristophGoethe University
(författare)
-
Karolinska InstitutetKarolinska University Hospital
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Haemophilia29:5, s. 1291-12981351-8216
-
Ingår i:Haemophilia : the official journal of the World Federation of Hemophilia29:5, s. 1291-12981365-2516
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ranta, Susanna
-
Motwani, Jayashr ...
-
Blatny, Jan
-
Bührlen, Martina
-
Carcao, Manuel
-
Chambost, Hervé
-
visa fler...
-
Escuriola, Carme ...
-
Fischer, Katheli ...
-
Kartal-Kaess, Mu ...
-
de Kovel, Marloe ...
-
Kenet, Gili
-
Male, Christoph
-
Nolan, Beatrice
-
d'Oiron, Roselin ...
-
Olivieri, Martin
-
Zapotocka, Ester
-
Andersson, Nadin ...
-
Königs, Christop ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Pediatrik
- Artiklar i publikationen
-
Haemophilia
-
Haemophilia : th ...
- Av lärosätet
-
Lunds universitet
-
Karolinska Institutet